Skip to search formSkip to main contentSkip to account menu

ABT-493

National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

QuinoxalinesSulfonamides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Corrigendum to "Second generation direct-acting antivirals - do we expect major improvements?"
2016
2016
High Efficacy of Abt-493 and Abt-530 in Hcv Genotype 1 Infected Patients who Have Failed Direct-Acting Antiviral-Containing Regimens: The Magellan-I Study
Review
2016
Review
2016
High Svr Rates with ABT-493 + ABT-530 Co-Administered for 8 Weeks in Non-Cirrhotic Patients with HCV Genotype 3 Infection
2016
2016
ABT-493 and ABT-530 Combination Demonstrated Minimal Potential for CYP-Mediated Drug-Drug Interactions
2016
2016
High SVR Rates with the Combination of ABT-493 + ABT-530 for 8 Weeks in Non-Cirrhotic Patients with HCV Genotype 1 or 2 Infection
2016
2016
Analysis of HCV Genotype 2 and 3 Variants in Patients Treated with Combination Therapy of Next Generation HCV Direct-Acting Antiviral Agents ABT-493 and ABT-530
Review
2016
Review
2016
Safety of ABT-493 and ABT-530 Co-Administered in Patients with HCV Genotype 1–6 Infection: Results from the Surveyor-I and Surveyor-II Studies
Review
2016
Review
2016
100% SVR4 and Favorable Safety of ABT-493 + ABT-530 Administered for 12 Weeks in Non-Cirrhotic Patients with Genotypes 4, 5, or 6 Infection (Surveyor-I)
Review
2016
Review
2016
High Efficacy and Favorable Safety of ABT-493 and ABT-530 Co-Administration for 12 Weeks in HCV Genotype 1-Infected Patients with Cirrhosis (Surveyor-I)
2015
2015
Industry chases pan-genotypic and shorter HCV treatments
575 replication to cure infection [using] all-oral drug [combinations] without interferon,” says Jean-Michel Pawlotsky, of the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)